<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Insulin Regular - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Insulin Regular</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Endocrine / Metabolic / Antidotes</div>
      <h1>Insulin Regular</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Insulin Regular 100 units/mL 10mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Diabetic ketoacidosis (DKA) / hyperglycemic emergency</strong>
            <ul>
              <li>Initial IV bolus: 0.1 units/kg (may omit bolus in some protocols; follow institutional guidelines)</li>
              <li>Continuous IV infusion: 0.1 units/kg/hour (typical range 5–10 units/hour for average adult)</li>
              <li>Adjust rate based on blood glucose response (target decrease ~50–75 mg/dL per hour)</li>
              <li>Requires close monitoring, IV fluids, electrolyte replacement, and medical direction</li>
            </ul>
          </li>
          <li><strong>Hyperglycemia (non-emergency; SC correction dose)</strong>
            <ul>
              <li>Highly individualized; depends on insulin sensitivity, current glucose, and home regimen</li>
              <li>Example correction scale (for reference; adjust per patient/protocol):
                <ul>
                  <li>Glucose 10–15 mmol/L (180–270 mg/dL): 2–4 units SC</li>
                  <li>Glucose 15–20 mmol/L (270–360 mg/dL): 4–6 units SC</li>
                  <li>Glucose &gt;20 mmol/L (&gt;360 mg/dL): 6–8 units SC and reassess urgently</li>
                </ul>
              </li>
              <li>Reassess blood glucose in 1–2 hours; repeat as needed</li>
            </ul>
          </li>
          <li><strong>Hyperkalemia (adjunct treatment with dextrose)</strong>
            <ul>
              <li>10 units regular insulin IV with 25–50 g dextrose (e.g., 50 mL D50W) to shift potassium intracellularly</li>
              <li>Monitor blood glucose closely (risk of hypoglycemia)</li>
              <li>Follow emergency hyperkalemia protocols</li>
            </ul>
          </li>
          <li><strong>Sliding scale / meal coverage (if no other insulin available)</strong>
            <ul>
              <li>Give SC 30 minutes before meals; dose based on carbohydrate intake and blood glucose</li>
              <li>Not ideal for routine meal coverage (rapid-acting analogs preferred when available)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS)</li>
          <li>Acute hyperglycemia requiring rapid correction</li>
          <li>Hyperkalemia management (with dextrose)</li>
          <li>Blood glucose control in hospitalized/critically ill patients (IV infusion)</li>
          <li>Basal-bolus insulin regimen (when other insulin formulations unavailable; not ideal for routine use)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypoglycemia (do not give if blood glucose is low)</li>
          <li>Hypersensitivity to insulin or product components (rare)</li>
          <li>Ensure correct insulin type and dose; insulin errors can be fatal</li>
          <li>Use insulin syringes (U-100) to avoid dosing errors; do not use tuberculin syringes</li>
          <li>IV use: only regular insulin can be given IV; do NOT give other insulin types IV</li>
          <li>Renal/hepatic impairment: insulin requirements may change; monitor closely</li>
          <li>Illness, infection, stress: may increase insulin requirements</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Hypoglycemia (most common and serious): sweating, tremor, confusion, seizure, loss of consciousness</li>
          <li>Hypokalemia (especially with treatment of DKA; monitor and replace potassium)</li>
          <li>Injection site reactions (pain, redness, lipohypertrophy with repeated use at same site)</li>
          <li>Weight gain (with chronic use)</li>
          <li>Rarely: severe allergic reaction, insulin antibody formation</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>SC injection:</strong>
            <ul>
              <li>Use U-100 insulin syringe; draw up dose carefully and verify</li>
              <li>Inject into SC tissue (abdomen, thigh, upper arm); rotate sites</li>
              <li>Onset ~30 minutes; peak 2–4 hours; duration ~6–8 hours</li>
              <li>Give 30 minutes before meals if using for meal coverage</li>
            </ul>
          </li>
          <li><strong>IV administration (DKA, critical care):</strong>
            <ul>
              <li>Dilute in 0.9% NaCl (typically 100 units in 100 mL = 1 unit/mL)</li>
              <li>Use infusion pump; ensure dedicated IV line or compatible with other infusions</li>
              <li>Prime tubing (insulin binds to plastic; first 20–50 mL may be wasted)</li>
              <li>Monitor blood glucose hourly initially</li>
            </ul>
          </li>
          <li>Storage: Refrigerate unopened vials; opened vials can be kept at room temperature for 28 days; protect from heat/light</li>
          <li>Check expiration date; do not use if discolored or contains particles (regular insulin is clear)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Blood glucose: frequently (hourly during IV infusion; every 1–4 hours with SC dosing depending on stability)</li>
          <li>Signs/symptoms of hypoglycemia: sweating, tremor, confusion, tachycardia, seizure (treat immediately with glucose/dextrose)</li>
          <li>Electrolytes (especially potassium) during DKA treatment or IV insulin infusion</li>
          <li>Ketones (if DKA): monitor until resolution</li>
          <li>Acid-base status (if treating DKA)</li>
          <li>Patient's usual insulin regimen and adherence (if chronic diabetic)</li>
          <li>Have dextrose/glucagon readily available for hypoglycemia treatment</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>High-risk medication: double-check dose, concentration, route, and patient before administration</li>
          <li>For DKA: requires intensive monitoring, IV access, fluids, electrolyte replacement—consider urgent evacuation if feasible</li>
          <li>If limited lab capability: use point-of-care glucose meter; monitor clinical response closely</li>
          <li>Hypoglycemia is life-threatening: have oral glucose, dextrose IV (D50W or D10W), and glucagon available</li>
          <li>If patient is on home insulin: verify type, dose, timing, and last dose before giving additional insulin</li>
          <li>For hyperglycemia without DKA: conservative SC dosing with frequent glucose checks; reassess if not improving</li>
          <li>Document dose, time, route, blood glucose before/after, and clinical response clearly</li>
          <li>Insulin storage critical: refrigerate when possible; if no refrigeration, keep cool and use within stability window</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (insulin regular - Humulin R): <a href="https://pdf.hres.ca/dpd_pm/00066193.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00066193.PDF</a></li>
          <li>Health Canada product monograph (insulin regular - Novolin ge Toronto): <a href="https://pdf.hres.ca/dpd_pm/00059030.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00059030.PDF</a></li>
          <li>Medscape - Insulin Regular: <a href="https://reference.medscape.com/drug/humulin-r-novolin-r-insulin-regular-999315" target="_blank" rel="noopener">https://reference.medscape.com/drug/humulin-r-novolin-r-insulin-regular-999315</a></li>
          <li>Diabetes Canada - Diabetic Ketoacidosis: <a href="https://guidelines.diabetes.ca/cpg/chapter35" target="_blank" rel="noopener">https://guidelines.diabetes.ca/cpg/chapter35</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
